| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.01 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.16 | 0.01 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |